中国医药
中國醫藥
중국의약
CHINA MEDICINE
2011年
2期
134-136
,共3页
癌,非小细胞肺%多西他赛%吉西他滨%顾铂
癌,非小細胞肺%多西他賽%吉西他濱%顧鉑
암,비소세포폐%다서타새%길서타빈%고박
Cancer,non-small cell lung%Docetaxel%Gemcitabine%Cisplatin
目的 比较多西他赛与吉西他滨联合顺铂方案治疗晚期非小细胞肺癌(NSCLC)的临床疗效及不良反应.方法 120例晚期非小细胞肺癌患者完全随机分为2组.多西他赛组60例给予多西他赛37.5 mg/m2,第1、8天;顺铂25 mg/m2,第1～3天.吉西他滨组60例给予吉西他滨1000 mg/m2,第1、8天;顾铂用量同前.化疗每3周重复,每周期评价不良反应,评价疗效并随访生存期.结果 20例患者均可评价疗效和不良反应,2组有效率分别为多西他赛组45.0%(27/60)和吉西他滨组43.3%(26/60),1年生存率分别为45%和43.3%,两组之间有效率和1年生存率均无统计学意义(P＞0.05).不良反应主要为骨髓抑制和肝功能损害[多西他赛组白细胞产减少率为85.0%(51/60),吉西他滨组为78.0%(47/60),2组差异无统计学意义(P＞0.05);2组肝功能损害率分别为33.3%(20/60)、26.7%(16/60),差异有统计学意义(P＜0.05)].结论 多西他赛与吉西他滨联合顺铂方案治疗晚期NSCLC均具有较好的疗效,且两者的疗效相似,不良反应可以耐受,可以作为临床一线治疗.
目的 比較多西他賽與吉西他濱聯閤順鉑方案治療晚期非小細胞肺癌(NSCLC)的臨床療效及不良反應.方法 120例晚期非小細胞肺癌患者完全隨機分為2組.多西他賽組60例給予多西他賽37.5 mg/m2,第1、8天;順鉑25 mg/m2,第1～3天.吉西他濱組60例給予吉西他濱1000 mg/m2,第1、8天;顧鉑用量同前.化療每3週重複,每週期評價不良反應,評價療效併隨訪生存期.結果 20例患者均可評價療效和不良反應,2組有效率分彆為多西他賽組45.0%(27/60)和吉西他濱組43.3%(26/60),1年生存率分彆為45%和43.3%,兩組之間有效率和1年生存率均無統計學意義(P＞0.05).不良反應主要為骨髓抑製和肝功能損害[多西他賽組白細胞產減少率為85.0%(51/60),吉西他濱組為78.0%(47/60),2組差異無統計學意義(P＞0.05);2組肝功能損害率分彆為33.3%(20/60)、26.7%(16/60),差異有統計學意義(P＜0.05)].結論 多西他賽與吉西他濱聯閤順鉑方案治療晚期NSCLC均具有較好的療效,且兩者的療效相似,不良反應可以耐受,可以作為臨床一線治療.
목적 비교다서타새여길서타빈연합순박방안치료만기비소세포폐암(NSCLC)적림상료효급불량반응.방법 120례만기비소세포폐암환자완전수궤분위2조.다서타새조60례급여다서타새37.5 mg/m2,제1、8천;순박25 mg/m2,제1～3천.길서타빈조60례급여길서타빈1000 mg/m2,제1、8천;고박용량동전.화료매3주중복,매주기평개불량반응,평개료효병수방생존기.결과 20례환자균가평개료효화불량반응,2조유효솔분별위다서타새조45.0%(27/60)화길서타빈조43.3%(26/60),1년생존솔분별위45%화43.3%,량조지간유효솔화1년생존솔균무통계학의의(P＞0.05).불량반응주요위골수억제화간공능손해[다서타새조백세포산감소솔위85.0%(51/60),길서타빈조위78.0%(47/60),2조차이무통계학의의(P＞0.05);2조간공능손해솔분별위33.3%(20/60)、26.7%(16/60),차이유통계학의의(P＜0.05)].결론 다서타새여길서타빈연합순박방안치료만기NSCLC균구유교호적료효,차량자적료효상사,불량반응가이내수,가이작위림상일선치료.
Objective To compare the efficacy and safety of docetaxel plus cisplatin and gemcitabine plus cisplatin in advanced non-small cell lung cancer (NSCLC). Methods A total of 120 patients with advanced NSCLC were divided into two groups. The patients received docetaxel in docetaxel group. In gemcitabine group the patients received gemcitabine and cisplatin. The treatment schedule was repeated every 3 weeks. The toxicity,quality response and survival rate of life were evaluated after every cycle. Results The response rates of the docetaxel group and the gemcitabine group were 45% and 43.3%,respectively. One-year survival rates in the two groups were 45% and 43.3%,respectively. The response rate,one-year survival time showed no significance (P ＞0.05). The main side effects were myelosupp ression,nausea and vomiting. Conclusion Regimens of DC and GC are both safe and effective in the treatment of advanced stage NSCLC. They can be used as the first regimen of chemotherapy in patients with advanced stage NSCLC.
